MedPath

Tokyo Oral Immunotherapy and Probiotics for Milk allergy (TOY) Study

Phase 2
Conditions
Milk allergy
Registration Number
JPRN-jRCTs031180180
Lead Sponsor
Ohya Yukihiro
Brief Summary

As the primary outcome, the proportion of children showing improvement at the threshold dose to cow's milk determined by OFC at the end of the intervention period had no significant differences between LP0132-fermented juice group and placebo group. The adherence to the intake of citrus juice fermented with LP0132 was good. It was considered safe to add citrus juice fermented with LP0132 to cow's milk oral immunotherapy, because there was no difference in the occurrence of AEs compared with placebo group.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
61
Inclusion Criteria

1) Cow's milk allergy diagnosed by an oral food challenge test.
2) Children who have a plan to take oral immunotherapy for cow's milk allergy.
3) 1-18 years old children with parental signed informed consent.
4) Voluntary willingness and ability to comply with the study requirements and procedure after obtaining informed consent.

Exclusion Criteria

1) Allergy to study juice and citrus.
2) Taking oral immunotherapy for the other foods except for cow's milk.
3) Children born before 37 weeks of gestation.
4) Twin or multiple births.
5) Children who participate in other clinical studies.
6) Children whose siblings participate in this study.
7) Taking immunosuppressive agents and/or oral and/or intravenous steroids.
8) Children whose family may not complete all study visits because of house-moving.
9) Parents unable to understand Japanese.
10) Children with any severe comorbidity.
11) Children judged as inappropriate for the study by a study doctor.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The proportion of participants who were improved on their threshold dose to cow's milk provoked with oral food challenge test after completing the intervention for 24 weeks.
Secondary Outcome Measures
NameTimeMethod
Adherence<br>consumed volume and days of taking the study juice <br>days of oral immunotherapy for cow's milk allergy<br><br>Feasibility<br>the participation rate of the study<br>the withdrawal rate of the study<br>deviation rate of the study<br><br>Efficacy<br>the change from baseline after the end of intervention for 24 weeks in cow's milk, casein and beta-lactoglobulin-specific IgE in serum.<br>the change from baseline after the end of intervention for 24 weeks in casein and beta-lactoglobulin-specific IgG4 in serum.<br>the dose of milk intake in oral immunotherapy at the end of the intervention for 24 weeks.<br><br>Exploratory<br>the change from baseline after the end of intervention for 24 weeks in cytokines and chemokines.<br>gut microbiota after the end of intervention for 24 weeks in gut microbiota.
© Copyright 2025. All Rights Reserved by MedPath